Celiac Disease
Conditions
Keywords
celiac disease, refractory celiac disease, gluten sensitivity
Brief summary
The main purpose of this study is to see how cells taken from the lining of the intestine behave in the laboratory with exposure to gluten and other substances that act on the immune system. The cells lining the intestine of a person with celiac disease should be different than a person without celiac disease. The study doctors would like to see how the cells react after coming in contact with gluten and if substances that act on the immune system can prevent gluten related inflammation. Examples of these substances include steroids. The cells should produce chemicals of their own in response to the gluten. These other chemicals will be measured and the results compared between those with: * celiac disease that does not respond to a gluten-free diet (refractory celiac disease) * celiac disease which is controlled by a gluten-free diet * uncontrolled celiac disease (either newly diagnosed with celiac disease or not on a gluten-free diet * gluten-sensitivity * disorders other than celiac disease.
Detailed description
The primary purpose of this study is to determine the effect of in-vitro introduction of gluten on inflammatory response primarily Interferon-γ and other cytokines, such as IL-15, IL-18 and IL-21, in cultures obtained from small intestinal mucosal biopsy samples of subjects who underwent upper endoscopy. Secondary goals include comparing the inflammatory response to immunosuppressants and cytokines after exposing the cultures obtained from small intestinal mucosal biopsies taken from RCD I subjects with intestinal mucosal biopsies taken from subjects with CeD controlled on a Gluten-Free Diet (GFD), uncontrolled CeD, Gluten sensitivity and Non-celiac Controls.
Interventions
None listed
Sponsors
Beth Israel Deaconess Medical Center
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* 18-75 years of age * Undergoing a clinically indicated upper endoscopy
Exclusion criteria
* Anticoagulation or antiplatelet therapy * Known active non-celiac intestinal inflammatory disorder
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| change in interferon gamma | 0, 6, and 24 hours | in vitro culture stimulated with gluten |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| change in interleukin-15 | 0, 6, and 24 hours | in vitro culture stimulated with gluten |
| change in interleukin-18 | 0, 6, and 24 hours | in vitro culture stimulated with gluten |
| change in interleukin-21 | 0, 6, and 24 hours | in vitro culture stimulated with gluten |
Countries
United States
Outcome results
None listed